Clinical Trial Update: Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial assessing recombinant human Clara Cell 10 Protein (rhCC10) for respiratory distress syndrome in premature neonates; results have been posted after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia
• Respiratory Distress Syndrome in Premature Infant

Drugs mentioned

• recombinant human Clara Cell 10 Protein (rhCC10) (rhCC10)

Snippet

Sponsor: Tufts Medical Center | Conditions: Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia | Phase 2 | Status: COMPLETED | Results posted: 2019-09-10